Updated Jul 16, 2026
Gleason Shane Thomas has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $289K.

Shane Thomas Gleason is an executive at InspireMD, Inc., serving as Chief Commercial Officer. In the SEC filing dated January 16, 2026, he is listed as Chief Commercial Officer with total purchases of $0 and total sales of $0 in that filing. InspireMD focuses on the MicroNet stent platform and markets products such as the CGuard carotid Embolic Prevention System (EPS) and MGuard Prime EPS.
| Role | Chief Commercial Officer |
|---|---|
| Notability | 40/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 22.8K | $1.01 | $23K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 2.9K | $1.59 | $5K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 7.2K | $2.51 | $18K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 3.8K | $2.51 | $9K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 1.6K | $2.51 | $4K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 2.5K | $2.51 | $6K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 10.0K | $3.65 | $36K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 5.1K | $2.46 | $13K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 7.1K | $2.51 | $18K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 9.9K | $2.55 | $25K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 2.5K | $2.51 | $6K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 3.7K | $2.46 | $9K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 2.5K | $2.61 | $6K |
| 2026-05-21 | NSPR | InspireMD, Inc. | S — Open-market sale | 3.9K | $2.71 | $10K |
| 2026-02-02 | NSPR | InspireMD, Inc. | S — Open-market sale | 2.0K | $1.60 | $3K |
| 2026-02-02 | NSPR | InspireMD, Inc. | S — Open-market sale | 2.9K | $1.63 | $5K |
| 2026-02-02 | NSPR | InspireMD, Inc. | S — Open-market sale | 5.0K | $1.65 | $8K |
| 2026-02-02 | NSPR | InspireMD, Inc. | S — Open-market sale | 12.4K | $1.65 | $20K |
| 2026-02-02 | NSPR | InspireMD, Inc. | S — Open-market sale | 4.8K | $1.66 | $8K |
| 2026-02-02 | NSPR | InspireMD, Inc. | S — Open-market sale | 8.4K | $1.57 | $13K |
Shane Thomas Gleason is an executive at InspireMD, Inc., serving as Chief Commercial Officer. In the SEC filing dated January 16, 2026, he is listed as Chief Commercial Officer with total purchases of $0 and total sales of $0 in that filing. InspireMD focuses on the MicroNet stent platform and markets products such as the CGuard carotid Embolic Prevention System (EPS) and MGuar…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 24 open-market sales ($289K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gleason Shane Thomas profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.